Clinical Study
Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease
Table 3
Drugs withdrawn according to different factors.
| | | | Drugs withdrawn | | | | None | HBIG | HBIG and nucleoside analogues |
| | Donor anti-HBs status | Positive | 0 | 6 | 3 | | Negative | 5 | 18 | 18 |
| | Vaccine type | Engerix-B | 4 | 3 | 13 | | Twinrix | 1 | 21 | 8 |
| Recipient HBV DNA
before OLT (copies/mL) | ≥103 | 2 | 7 | 10 | | <103 | 3 | 17 | 11 |
| | Primary disease before OLT | Liver failure (LF) | 0 | 7 | 5 | | Liver cirrhosis (LC) | 4 | 9 | 9 | | Hepatocellular carcinoma (HCC) | 1 | 2 | 1 | | HCC and LC | 0 | 6 | 6 |
|
|
